Curious to see your top suppliers emissions?
Book a demo for a pilot project
M
MedImmune, LLC
Pharmaceutical Preparation ManufacturingUnited States
Last verified 1 year ago
MedImmune, LLC, a subsidiary of AstraZeneca, is a leading biotechnology company headquartered in the United States. Founded in 1988, MedImmune has established itself as a key player in the biopharmaceutical industry, focusing on the development of innovative therapies for respiratory, oncology, and infectious diseases.
With major operational regions across North America and Europe, MedImmune is renowned for its pioneering work in monoclonal antibodies and biologics. The company’s flagship products, including Synagis and FluMist, are distinguished by their unique mechanisms of action and significant clinical impact.
MedImmune's commitment to research and development has positioned it as a market leader, achieving notable milestones such as the successful launch of groundbreaking therapies that address unmet medical needs. Through its dedication to advancing science and improving patient outcomes, MedImmune continues to shape the future of healthcare.
100
DitchCarbon score
+60 vs industry average
MedImmune, LLC’s score of 100 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at MedImmune, LLC?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for MedImmune, LLC yet.
MedImmune, LLC's reported carbon emissions
MedImmune, LLC, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of AstraZeneca PLC, which means that its climate commitments and emissions data are inherited from its parent organisation.
AstraZeneca has set ambitious climate targets, including commitments to reduce greenhouse gas emissions across its operations. These targets are part of a broader strategy to achieve net-zero emissions by 2025 for its own operations (Scope 1 and 2) and by 2030 for its value chain (Scope 3). MedImmune, as part of AstraZeneca, aligns with these initiatives, although specific reduction targets for MedImmune itself have not been disclosed.
The company participates in various climate initiatives cascaded from AstraZeneca, including the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, which focuses on sourcing 100% renewable electricity. These commitments reflect a strong dedication to addressing climate change and reducing carbon footprints within the biopharmaceutical industry.
While specific emissions figures for MedImmune are not available, the overarching goals set by AstraZeneca indicate a proactive approach to sustainability and climate responsibility.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
MedImmune, LLC’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for MedImmune, LLC yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from AstraZeneca PLCSee details
Not active
Carbon Disclosure Project
Inherited from AstraZeneca PLCSign in to view
Active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
Inherited from AstraZeneca PLCSee details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for MedImmune, LLC yet.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more